Kiniksa Pharmaceuticals International (KNSA) Accumulated Expenses (2017 - 2026)

Kiniksa Pharmaceuticals International's Accumulated Expenses history runs 10 years deep, the most recent figure standing at $32.8 million for Q1 2026.

• Quarterly Accumulated Expenses rose 272.44% year-over-year to $32.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32.8 million (up 272.44% YoY) and the FY2025 annual result came in at $21.4 million, up 211.54% from the prior year.
• Accumulated Expenses was $32.8 million for Q1 2026 at Kiniksa Pharmaceuticals International, up from $21.4 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $38.9 million in Q1 2022 and bottomed at $5.6 million in Q1 2023.
• A 5-year average of $17.0 million and a median of $11.5 million in 2024 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Accumulated Expenses surged 445.4% — and 2023, when it plunged 85.49%.
• Kiniksa Pharmaceuticals International's Accumulated Expenses stood at $11.2 million in 2022, then jumped by 147.28% to $27.7 million in 2023, then tumbled by 75.18% to $6.9 million in 2024, then surged by 211.54% to $21.4 million in 2025, then surged by 52.87% to $32.8 million in 2026.
• Business Quant data shows KNSA's Accumulated Expenses at $32.8 million in Q1 2026, $21.4 million in Q4 2025, and $30.9 million in Q3 2025.